☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

NICE rimonabant advice withdrawn

The National Institute for Heath and Clinical Excellence has withdrawn its guidance on the use of rimonabant for the treatment of overweight and obese patients.

The withdrawal of this guidance is as a result of suspension of the marketing authorisation for rimonabant (Acomplia®) by the European Medicines Agency (EMEA) for safety reasons.

Action: Clinicians should already be aware of this license suspension. No new prescriptions should be issued and patients should be advised that it is safe to stop treatment at any time.

Share 'NICE rimonabant advice withdrawn' by emailShare 'NICE rimonabant advice withdrawn' on FacebookShare 'NICE rimonabant advice withdrawn' on TwitterShare 'NICE rimonabant advice withdrawn' on LinkedInShare 'NICE rimonabant advice withdrawn' on reddit


No Comments to “NICE rimonabant advice withdrawn”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.